Patents by Inventor Henry G. Lamparski

Henry G. Lamparski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
    Patent number: 7011976
    Abstract: Replication competent adenoviral vectors specific for cells expressing alfa-fetoprotein (AFP) are provided. These replication-competetent adenoviral vectors comprise adenovirus genes essential for replication under the transcriptional control of an AFP-transcriptional regulatory element.
    Type: Grant
    Filed: March 3, 1998
    Date of Patent: March 14, 2006
    Assignee: Calydon, Inc.
    Inventors: Andrew S. Little, Henry G. Lamparski, Daniel R. Henderson, Eric R. Schuur
  • Compositions comprising tissue specific adenoviral vectors
    Patent number: 7001764
    Abstract: Compositions comprising host cell specific adenovirus vehicles are provided for transfecting target host cells. The compositions comprise replication competent adenovirus having an adenovirus gene essential for replication under transcriptional control of a cell type specific transcriptional response element (TRE) and polyethylene glycol (PEG) as a masking agent.
    Type: Grant
    Filed: May 2, 2002
    Date of Patent: February 21, 2006
    Assignee: Cell Genesys, Inc.
    Inventors: Andrew S. Little, Henry G. Lamparski, Daniel R. Henderson, Eric R. Schuur
  • Compositions comprising tissue specific adenoviral vectors
    Publication number: 20030152553
    Abstract: Compositions comprising host cell specific adenovirus vehicles are provided for transfecting target host cells. The compositions comprise replication competent adenovirus having an adenovirus gene essential for replication under transcriptional control of a cell type specific transcriptional response element (TRE) and polyethylene glycol (PEG) as a masking agent.
    Type: Application
    Filed: May 2, 2002
    Publication date: August 14, 2003
    Inventors: Andrew S. Little, Henry G. Lamparski, Daniel R. Henderson, Eric R. Schuur
  • Prostate cancer drug screening using hKLK2 enhancer
    Patent number: 6051417
    Abstract: Screening of compounds for activity toward inhibition of prostate cancer cell proliferation is provided. A cell line containing an expression construct comprising a transciptional initiation region of a prostate specific enhancer from a human glandular kallikrein (hKLK2) gene is employed which can be used in conventional equipment for determining activity of compounds, where the cell line uses a marker whose expression is responsive to therapeutically active compounds.
    Type: Grant
    Filed: August 4, 1997
    Date of Patent: April 18, 2000
    Assignee: Calydon, Inc.
    Inventors: Daniel R. Henderson, Eric R. Schuur, Henry G. Lamparski, De-Chao Yu
  • Prostate cancer drug screenings
    Patent number: 5783435
    Abstract: Screening of compounds for activity toward inhibition of prostate cancer cell proliferation is provided. A cell line is employed which can be used in conventional equipment for determining activity of compounds, where the cell line uses a marker whose expression is responsive to therapeutically active compounds.
    Type: Grant
    Filed: August 6, 1996
    Date of Patent: July 21, 1998
    Inventors: Henry G. Lamparski, Eric R. Schuur, Daniel R. Henderson